These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32284318)

  • 1. An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer.
    Brave M; Weinstock C; Brewer JR; Chi DC; Suzman DL; Cheng J; Zhang L; Sridhara R; Ibrahim A; Kluetz PG; Pazdur R; Beaver JA
    Clin Cancer Res; 2020 Sep; 26(18):4717-4722. PubMed ID: 32284318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
    J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darolutamide in hormone-sensitive and castration-resistant prostate cancer.
    Palmieri VE; Roviello G; D'Angelo A; Casadei C; De Giorgi U; Giorgione R
    Expert Rev Clin Pharmacol; 2021 May; 14(5):535-544. PubMed ID: 33685318
    [No Abstract]   [Full Text] [Related]  

  • 4. Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis.
    Roumiguié M; Paoletti X; Neuzillet Y; Mathieu R; Vincendeau S; Kleinclauss F; Mejean A; Guy L; Timsit MO; Lebret T
    Future Oncol; 2021 May; 17(14):1811-1823. PubMed ID: 33543650
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors.
    Appukkuttan S; Ko G; Fu C; Bannister B; Kong SX; Jhaveri J; Freedland SJ
    Expert Rev Anticancer Ther; 2024 May; 24(5):325-333. PubMed ID: 38469875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
    Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in the treatment of non-metastatic castration resistant prostate cancer.
    Esther J; Dorff TB; Maughan BL
    Cancer Treat Res Commun; 2020; 24():100181. PubMed ID: 32673844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
    Hussain A; Jiang S; Varghese D; Appukkuttan S; Kebede N; Gnanasakthy K; Macahilig C; Waldeck R; Corman S
    BMC Cancer; 2022 Mar; 22(1):304. PubMed ID: 35317768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
    Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Tombal B; Sternberg CN; Hussain M; Ganguli A; Li Y; Sandin R; Bhadauria H; Oh M; Saad F
    ESMO Open; 2022 Jun; 7(3):100510. PubMed ID: 35714477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents.
    Rizzo A; Oderda M; Mollica V; Merler S; Morelli F; Fragomeno B; Taveri E; Sorgentoni G; Santoni M; Massari F
    Anticancer Drugs; 2022 Jan; 33(1):e43-e51. PubMed ID: 34387593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
    Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
    Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment and trials in non-metastatic castration-resistant prostate cancer.
    Lokeshwar SD; Klaassen Z; Saad F
    Nat Rev Urol; 2021 Jul; 18(7):433-442. PubMed ID: 34002069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
    George DJ; Morgans AK; Constantinovici N; Khan N; Khan J; Chen G; Hlebec V; Shore ND
    JAMA Netw Open; 2024 Aug; 7(8):e2429783. PubMed ID: 39190308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
    Appukkuttan S; Farej R; Miles L; Purser M; Wen L
    J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
    [No Abstract]   [Full Text] [Related]  

  • 16. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.
    Small EJ; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; De Porre P; Smith AA; Zhang K; Lopez-Gitlitz A; Smith MR
    Ann Oncol; 2019 Nov; 30(11):1813-1820. PubMed ID: 31560066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.
    Shore N; Jiang S; Garcia-Horton V; Terasawa E; Steffen D; Chin A; Ayyagari R; Partridge J; Waldeck AR
    Adv Ther; 2022 Nov; 39(11):5025-5042. PubMed ID: 36028656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
    Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
    Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.
    Swami U; Agarwal N
    Cancer Treat Res Commun; 2020; 25():100205. PubMed ID: 32822968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer.
    Graff JN; Liang LW; Kim J; Stenzl A
    Future Oncol; 2021 Aug; 17(23):3017-3026. PubMed ID: 34044584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.